 Jeffrey Olsen
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 11 | 2024 | 121 | 4.330 |
Why?
| | Chemoradiotherapy | 11 | 2021 | 188 | 2.660 |
Why?
| | Radiosurgery | 8 | 2020 | 299 | 2.570 |
Why?
| | Liver Neoplasms | 8 | 2020 | 506 | 1.980 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2019 | 124 | 1.960 |
Why?
| | Gastrointestinal Neoplasms | 6 | 2020 | 59 | 1.840 |
Why?
| | Anus Neoplasms | 3 | 2019 | 24 | 1.810 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 7 | 2020 | 117 | 1.810 |
Why?
| | Neoadjuvant Therapy | 9 | 2023 | 304 | 1.800 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2019 | 211 | 1.500 |
Why?
| | Adenocarcinoma | 10 | 2022 | 795 | 1.410 |
Why?
| | Radiotherapy, Image-Guided | 5 | 2020 | 30 | 1.230 |
Why?
| | Pancreatic Neoplasms | 8 | 2022 | 731 | 1.090 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 577 | 1.000 |
Why?
| | Esophageal Neoplasms | 3 | 2022 | 273 | 0.880 |
Why?
| | Radiation Oncology | 3 | 2021 | 75 | 0.870 |
Why?
| | Tomography, X-Ray Computed | 9 | 2020 | 2279 | 0.870 |
Why?
| | Colorectal Neoplasms | 3 | 2021 | 615 | 0.850 |
Why?
| | Magnetic Resonance Imaging | 7 | 2021 | 3039 | 0.830 |
Why?
| | Prostatic Neoplasms | 4 | 2015 | 921 | 0.820 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 1355 | 0.800 |
Why?
| | Radiotherapy Dosage | 8 | 2020 | 244 | 0.740 |
Why?
| | Magnetic Resonance Imaging, Interventional | 2 | 2019 | 20 | 0.710 |
Why?
| | Abdominal Neoplasms | 2 | 2016 | 26 | 0.670 |
Why?
| | Thoracic Neoplasms | 2 | 2016 | 32 | 0.660 |
Why?
| | Lymphatic Irradiation | 1 | 2019 | 9 | 0.660 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2012 | 216 | 0.630 |
Why?
| | Deglutition Disorders | 1 | 2018 | 118 | 0.560 |
Why?
| | Intestine, Small | 2 | 2017 | 122 | 0.550 |
Why?
| | Tumor Burden | 6 | 2018 | 259 | 0.550 |
Why?
| | Organs at Risk | 5 | 2020 | 30 | 0.540 |
Why?
| | Aged, 80 and over | 16 | 2019 | 6344 | 0.530 |
Why?
| | Neoplasms | 2 | 2020 | 2097 | 0.510 |
Why?
| | Catheter Ablation | 1 | 2018 | 288 | 0.490 |
Why?
| | Humans | 48 | 2024 | 114623 | 0.480 |
Why?
| | Multimodal Imaging | 2 | 2012 | 88 | 0.480 |
Why?
| | Fluorouracil | 5 | 2019 | 152 | 0.480 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2012 | 113 | 0.480 |
Why?
| | Positron-Emission Tomography | 2 | 2012 | 259 | 0.450 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 858 | 0.430 |
Why?
| | Prostate-Specific Antigen | 1 | 2013 | 151 | 0.420 |
Why?
| | Prone Position | 1 | 2012 | 27 | 0.410 |
Why?
| | Supine Position | 1 | 2012 | 32 | 0.400 |
Why?
| | Middle Aged | 21 | 2022 | 26719 | 0.380 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 222 | 0.360 |
Why?
| | Serpins | 1 | 2010 | 25 | 0.360 |
Why?
| | Aged | 18 | 2019 | 19061 | 0.360 |
Why?
| | Biomarkers, Tumor | 3 | 2018 | 1040 | 0.350 |
Why?
| | Early Detection of Cancer | 1 | 2013 | 328 | 0.340 |
Why?
| | Movement | 2 | 2011 | 244 | 0.330 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2013 | 961 | 0.330 |
Why?
| | Radiopharmaceuticals | 3 | 2018 | 157 | 0.330 |
Why?
| | Antigens, Neoplasm | 1 | 2010 | 221 | 0.320 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 510 | 0.320 |
Why?
| | Lung Neoplasms | 5 | 2013 | 2177 | 0.310 |
Why?
| | Neoplasm Staging | 5 | 2023 | 1167 | 0.310 |
Why?
| | Mitomycin | 2 | 2019 | 27 | 0.300 |
Why?
| | Tomography, Spiral Computed | 1 | 2007 | 23 | 0.300 |
Why?
| | Yttrium Radioisotopes | 2 | 2018 | 51 | 0.290 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 1879 | 0.280 |
Why?
| | Respiration | 1 | 2007 | 179 | 0.280 |
Why?
| | Algorithms | 3 | 2015 | 1466 | 0.260 |
Why?
| | Disease-Free Survival | 4 | 2017 | 620 | 0.260 |
Why?
| | Treatment Outcome | 9 | 2023 | 9084 | 0.250 |
Why?
| | Embolization, Therapeutic | 2 | 2018 | 178 | 0.250 |
Why?
| | Radiotherapy | 2 | 2017 | 176 | 0.250 |
Why?
| | Combined Modality Therapy | 3 | 2024 | 1121 | 0.240 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 275 | 0.240 |
Why?
| | Preoperative Care | 2 | 2017 | 319 | 0.230 |
Why?
| | Induction Chemotherapy | 3 | 2023 | 56 | 0.220 |
Why?
| | Pancreas | 2 | 2023 | 276 | 0.220 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2007 | 682 | 0.220 |
Why?
| | Organoplatinum Compounds | 3 | 2017 | 37 | 0.210 |
Why?
| | Leucovorin | 3 | 2017 | 43 | 0.210 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1075 | 0.200 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 811 | 0.190 |
Why?
| | Male | 17 | 2022 | 55554 | 0.180 |
Why?
| | Adult | 12 | 2018 | 30528 | 0.180 |
Why?
| | Female | 16 | 2022 | 59466 | 0.180 |
Why?
| | Biliary Tract Neoplasms | 1 | 2020 | 20 | 0.170 |
Why?
| | Workflow | 2 | 2020 | 133 | 0.170 |
Why?
| | Duodenum | 2 | 2016 | 62 | 0.160 |
Why?
| | Stomach | 2 | 2016 | 102 | 0.160 |
Why?
| | Technetium Tc 99m Aggregated Albumin | 1 | 2018 | 6 | 0.160 |
Why?
| | Serum Albumin, Human | 1 | 2018 | 3 | 0.160 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2018 | 45 | 0.150 |
Why?
| | Rectum | 3 | 2020 | 153 | 0.150 |
Why?
| | Bilirubin | 1 | 2018 | 88 | 0.150 |
Why?
| | Colon | 2 | 2017 | 233 | 0.150 |
Why?
| | Precision Medicine | 1 | 2021 | 336 | 0.150 |
Why?
| | Observer Variation | 2 | 2015 | 295 | 0.150 |
Why?
| | Matched-Pair Analysis | 1 | 2017 | 33 | 0.140 |
Why?
| | Follow-Up Studies | 4 | 2018 | 4411 | 0.140 |
Why?
| | Age Factors | 2 | 2017 | 2894 | 0.140 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 275 | 0.140 |
Why?
| | Microspheres | 1 | 2016 | 123 | 0.130 |
Why?
| | Pelvis | 1 | 2017 | 90 | 0.130 |
Why?
| | Pelvic Neoplasms | 1 | 2015 | 18 | 0.130 |
Why?
| | ROC Curve | 1 | 2017 | 442 | 0.130 |
Why?
| | Camptothecin | 1 | 2016 | 96 | 0.130 |
Why?
| | Lung | 1 | 2007 | 3558 | 0.120 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2015 | 22 | 0.120 |
Why?
| | Liposarcoma | 1 | 2015 | 26 | 0.120 |
Why?
| | Regression Analysis | 1 | 2017 | 944 | 0.120 |
Why?
| | Radiation Injuries | 1 | 2015 | 128 | 0.120 |
Why?
| | Acute Disease | 1 | 2017 | 910 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1394 | 0.110 |
Why?
| | Feasibility Studies | 1 | 2017 | 739 | 0.110 |
Why?
| | Prostate | 2 | 2015 | 156 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2022 | 12542 | 0.110 |
Why?
| | Gastrointestinal Tract | 1 | 2015 | 169 | 0.110 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.110 |
Why?
| | Patient Positioning | 1 | 2012 | 42 | 0.100 |
Why?
| | Thoracic Wall | 1 | 2012 | 14 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 517 | 0.100 |
Why?
| | Motion | 1 | 2012 | 90 | 0.100 |
Why?
| | Pneumonectomy | 1 | 2013 | 125 | 0.100 |
Why?
| | Image Enhancement | 1 | 2012 | 158 | 0.100 |
Why?
| | Software | 2 | 2016 | 529 | 0.100 |
Why?
| | Karnofsky Performance Status | 1 | 2011 | 36 | 0.090 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 427 | 0.090 |
Why?
| | Computer Systems | 1 | 2011 | 45 | 0.090 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2011 | 127 | 0.090 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 442 | 0.090 |
Why?
| | Rotation | 1 | 2011 | 110 | 0.090 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 37 | 0.090 |
Why?
| | Survival Analysis | 1 | 2012 | 1211 | 0.080 |
Why?
| | Quality Improvement | 1 | 2016 | 950 | 0.080 |
Why?
| | Capecitabine | 2 | 2020 | 45 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1691 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2011 | 1226 | 0.080 |
Why?
| | Prognosis | 2 | 2018 | 3328 | 0.070 |
Why?
| | Inhalation | 1 | 2007 | 26 | 0.070 |
Why?
| | Exhalation | 1 | 2007 | 35 | 0.070 |
Why?
| | Bile Duct Neoplasms | 1 | 2007 | 56 | 0.070 |
Why?
| | Artifacts | 1 | 2007 | 113 | 0.070 |
Why?
| | Deoxycytidine | 2 | 2019 | 138 | 0.070 |
Why?
| | Cohort Studies | 2 | 2016 | 4894 | 0.070 |
Why?
| | Pain | 1 | 2012 | 705 | 0.070 |
Why?
| | Quality of Life | 1 | 2016 | 2353 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2012 | 2762 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1430 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 2967 | 0.050 |
Why?
| | Trypanocidal Agents | 1 | 2002 | 1 | 0.050 |
Why?
| | Trypanosoma brucei rhodesiense | 1 | 2002 | 1 | 0.050 |
Why?
| | Diphosphonates | 1 | 2002 | 51 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 89 | 0.050 |
Why?
| | Survival Rate | 2 | 2018 | 1644 | 0.050 |
Why?
| | Paclitaxel | 1 | 2022 | 190 | 0.050 |
Why?
| | Watchful Waiting | 1 | 2021 | 55 | 0.050 |
Why?
| | Brachytherapy | 1 | 2020 | 103 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 473 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2020 | 311 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 445 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 86 | 0.040 |
Why?
| | Time Factors | 2 | 2018 | 6112 | 0.040 |
Why?
| | Lymphocytes | 1 | 2018 | 330 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 931 | 0.030 |
Why?
| | Duodenal Ulcer | 1 | 2016 | 10 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2016 | 64 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1214 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 410 | 0.030 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2015 | 13 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2015 | 23 | 0.030 |
Why?
| | Perioperative Period | 1 | 2015 | 49 | 0.030 |
Why?
| | Neutropenia | 1 | 2016 | 125 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2015 | 82 | 0.030 |
Why?
| | Penis | 1 | 2015 | 37 | 0.030 |
Why?
| | Anemia | 1 | 2016 | 143 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 262 | 0.030 |
Why?
| | Pancreatectomy | 1 | 2016 | 171 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2015 | 332 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2016 | 177 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2016 | 182 | 0.030 |
Why?
| | Sarcoma | 1 | 2015 | 137 | 0.030 |
Why?
| | Liver | 1 | 2021 | 1634 | 0.030 |
Why?
| | Urinary Bladder | 1 | 2015 | 162 | 0.030 |
Why?
| | Consensus | 1 | 2015 | 537 | 0.030 |
Why?
| | Neutrophils | 1 | 2018 | 1176 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2016 | 578 | 0.020 |
Why?
| | Treatment Failure | 1 | 2013 | 331 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 3408 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 522 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1796 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1036 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2380 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 872 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 6217 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 1840 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2016 | 2128 | 0.020 |
Why?
| | Risk Factors | 1 | 2018 | 8628 | 0.020 |
Why?
| | Lethal Dose 50 | 1 | 2002 | 12 | 0.010 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2002 | 13 | 0.010 |
Why?
| | United States | 1 | 2018 | 12176 | 0.010 |
Why?
| | Quantum Theory | 1 | 2002 | 78 | 0.010 |
Why?
| | Crystallography, X-Ray | 1 | 2002 | 402 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 849 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1369 | 0.010 |
Why?
| | Animals | 1 | 2002 | 31694 | 0.000 |
Why?
|
|
Olsen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|